東阿阿膠(000423.SZ)上半年預盈1.28億元-1.65億元 同比扭虧
格隆匯7月14日丨東阿阿膠(000423.SZ)披露2021年半年度業績預吿,公司預計2021年1-6月實現歸屬於上市公司股東的淨利潤1.28億元-1.65億元,上年同期為虧損8402萬元,同比實現扭虧為盈。
公司堅持以消費者為中心,堅定數字化轉型,豐富產品矩陣,推進組織變革,提升組織效能,釋放組織活力,以新增長邏輯,實現市場良性增長。
未來,公司持續提升顧客運營質量,加快數字轉型和商業模式升級,強化科研成果轉化與創新,推動品牌專業化、差異化,深入推進價值重塑、業務重塑、組織重塑、精神重塑,努力成為消費者信任的中式滋補健康引領者和中藥企業高質量發展的典範。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.